Current Diabetes Reports

, 19:85 | Cite as

Care of Children and Adolescents with Diabetes Mellitus and Hyperglycemia in the Inpatient Setting

  • Ishita Kharode
  • Emily Coppedge
  • Zoltan AntalEmail author
Hospital Management of Diabetes (A Wallia and JJ Seley, Section Editors)
Part of the following topical collections:
  1. Topical Collection on Hospital Management of Diabetes


Purpose of Review

Children and adolescents with acute hyperglycemia and diabetes mellitus frequently have acute, potentially life-threatening presentations which require high-acuity care in an inpatient and often intensive care setting. This review discusses the evaluation and care of hyperglycemia and diabetes mellitus in hospitalized children in both critical and non-critical care settings, highlighting important differences in their care relative to adults.

Recent Findings

Diabetic ketoacidosis remains highly prevalent at diagnosis among children with type 1 diabetes, and hyperglycemic hyperosmolar state is increasingly prevalent among children with type 2 diabetes. Recent clinical trials have investigated the potential benefits of various types of intravenous fluids and their rates of administration as well as the risks and benefits of intensive glucose control in critically ill children. The Endocrine Society has developed guidelines focused on managing hyperglycemic hyperosmolar state, outlining important aspects of care shown to decrease morbidity and mortality. In the non-critical illness setting, intensive therapy on newly diagnosed diabetes is increasingly recommended at the outset.


With the increasing incidence of diabetes mellitus in children and adolescents, recent studies addressing acute diabetes emergencies help inform best practices for care of hospitalized children with hyperglycemia and diabetes.


Pediatric diabetes Inpatient Hyperglycemia New-onset diabetes Diabetic ketoacidosis Hyperglycemic hyperosmolar state 


Compliance with Ethical Standards

Conflict of Interest

The authors declare that they have no conflict of interest.

Human and Animal Rights and Informed Consent

This article does not contain any studies with human or animal subjects performed by any of the authors.


Papers of particular interest, published recently, have been highlighted as: • Of importance •• Of major importance

  1. 1.
  2. 2.
    Mayer-Davis EJ, Lawrence JM, Dabelea D, Divers J, Isom S, Dolan L, et al. Incidence trends of type 1 and type 2 diabetes among youths, 2002–2012. N Engl J Med. 2017;376:1419–29. Scholar
  3. 3.
    Dabelea D. The accelerating epidemic of childhood diabetes. Lancet. 2009;373(9680):1999–2000. Scholar
  4. 4.
    American Diabetes Association. 2. Classification and diagnosis of diabetes: Standards of Medical Care in Diabetes – 2019. Diabetes Care. 2019;42(Suppl. 1):S13–28. Scholar
  5. 5.
    Raghupathy R. Diabetic ketoacidosis in children and adolescents. Indian J Endocrinol Metab. 2015;19(Suppl1):S55–7. Scholar
  6. 6.
    Dabelea D, Rewers A, Stafford JM, Standiford DA, Lawrence JM, Saydah S, et al. SEARCH for Diabetes in Youth Study Group. Trends in the prevalence of ketoacidosis at diabetes diagnosis: the SEARCH for diabetes in youth study. Pediatrics. 2014;133(4):e938–45. Scholar
  7. 7.
    Rewers A, Klingensmith G, Davis C, Petitti DB, Pihoker C, Rodriguez B, et al. Presence of diabetic ketoacidosis at diagnosis of diabetes mellitus in youth: the Search for Diabetes in Youth Study. Pediatrics. 2008;121(5):e1258–66. Scholar
  8. 8.
    Grobe J, Hornstein H, Manuwald U, Kugler J, Glauche I, Rothe U. Incidence of diabetic ketoacidosis of new-onset type 1 diabetes in children and adolescents in different countries correlates with human development index (HDI): an updated systematic review, meta-analysis, and meta-regression. Horm Metab Res. 2018;50(3):209–22. Scholar
  9. 9.
    Mallare JT, Cordice CC, Ryan BA, Carey DE, Kreitzer PM, Frank GR. Identifying risk factors for the development of diabetic ketoacidosis in new onset type 1 diabetes mellitus. Clin Pediatr (Phila). 2003;42(7):591–7. Scholar
  10. 10.
    Bui H, To T, Stein R, Fung K, Daneman D. Is diabetic ketoacidosis at disease onset a result of missed diagnosis? J Pediatr. 2010 Mar;156(3):472–7. Scholar
  11. 11.
    Karges B, Schwandt A, Heidtmann B, Kordonouri O, Binder E, Schierloh U, et al. Association of insulin pump therapy vs insulin injection therapy with severe hypoglycemia, ketoacidosis and glycemic control among children, adolescents, and young adults with type 1 diabetes. JAMA. 2017;318(14):1358–66. Scholar
  12. 12.
    Wolfsdorf JI. Diabetic ketoacidosis in infants, children, and adolescents. Diabetes Care. 2006;29(5):1150–9.CrossRefGoogle Scholar
  13. 13.
    Dunger DB, Sperling MA, Acerini CL, Bohn DJ, Daneman D, Danne TP, et al. European Society for Paediatric Endocrinology/Lawson Wilkins Pediatric Endocrine Society consensus statement of diabetic ketoacidosis in children and adolescents. Pediatrics. 2004;113(2):e133–8.CrossRefGoogle Scholar
  14. 14.
    Wolfsdorf JI, Allgrove J, Craig ME, Edge J, Glasser N, Jain V, et al. ISPAD clinical practice consensus guidelines 2014: diabetic ketoacidosis and hyperglycemic hyperosmolar state. Pediatr Diabetes. 2014;15(Suppl. 20):154–79. Scholar
  15. 15.
    • Kuppermann N, Ghetti S, Schunk J, Stoner MJ, Rewers A, McManemy JK, et al. Clinical trial of fluid infusion rates for pediatric diabetic ketoacidosis. N Engl J Med. 2018;378(24):2275–87. This study prospectively studied the still-controversial idea of whether rapid fluid administration leads to potentially adverse outcomes in pediatric DKA< and found no such association.CrossRefPubMedPubMedCentralGoogle Scholar
  16. 16.
    Hsia DS, Tarai SG, Alimi A, Cross-Bu JA, Haymond MW. Fluid management in pediatric patients and rates of suspected clinical cerebral edema. Pediatr Diabetes. 2015;16(5):338–44. Scholar
  17. 17.
    White PC, Dickson BA. Low morbidity and mortality in children with diabetic ketoacidosis treated with isotonic fluids. J Pediatr. 2013;163(3):761–6. Scholar
  18. 18.
    Basnet S, Venepalli PK, Andoh J, Verhulst S, Koirala J. Effect of normal saline and half normal saline on serum electrolytes during recovery phase of diabetic ketoacidosis. J Intensive Care Med. 2014;29(1):38–42. Scholar
  19. 19.
    Toledo JD, Modesto V, Peinador M, Alvarez P, Lopez-Prats JL, Sanchis R, et al. Sodium concentration in rehydration fluids for children with ketoacidotic diabetes: effect on serum sodium concentration. J Pediatr. 2009;154:895–900. Scholar
  20. 20.
    Puttha R, Cooke D, Subbarayan A, Odeka E, Ariyawansa I, Bone M, et al. Low dose (0.05 units/kg/h) is comparable with standard dose (0.1 units/kg/h) intravenous insulin infusion for the initial treatment of diabetic ketoacidosis in children with type 1 diabetes—an observational study. Pediatr Diabetes. 2010;11(1):12–7. Scholar
  21. 21.
    Nallasamy K, Jayashree M, Singhi S, Bansal A. Low-dose vs standard-dose insulin in pediatric diabetic ketoacidosis. JAMA Pediatr. 2014;168(11):999–1005. Scholar
  22. 22.
    Fort P, Walters SM, Lifshitz F. Low-dose insulin infusion in the treatment of diabetic ketoacisosi: bolus versus no bolus. J Pediatr. 1980;96(1):36–40.CrossRefGoogle Scholar
  23. 23.
    Goyal N, Miller JB, Sankey SS, Mossallam U. Utility of initial bolus insulin in the treatment of diabetic ketoacidosis. J Emerg Med. 2010;38(4):422–7. Scholar
  24. 24.
    Cohen M, Leibovitz N, Shilo S, Zuckerman-Levin N, Shavit I, Shehadeh N. Subcutaneous regular insulin for the treatment of diabetic ketoacidosis in children. Pediatr Diabetes. 2017;18:290–6. Scholar
  25. 25.
    Della Manna T, Steinmetz L, Campos PR, Farhat SC, SChvartsman C, Kuperman H, et al. Subcutaneous use of a fast-acting insulin analog: an alternative treatment for pediatric patients with diabetic ketoacidosis. Diabetes Care. 2005;28:1856–61.CrossRefGoogle Scholar
  26. 26.
    Glaser NS, Wootton-Gorges SL, Marcin JP, Buonocore MH, Dicarto J, Neely EK, et al. Mechanism of cerebral edema in children with diabetic ketoacidosis. J Pediatr. 2004;145:164–71.CrossRefGoogle Scholar
  27. 27.
    Glaser N, Barnett P, McCaslin I, Nelson D, Trainor J, Louie J, et al. Risk factors for cerebral edema in children with diabetic ketoacidosis. N Engl J Med. 2001;344(4):264–9.CrossRefGoogle Scholar
  28. 28.
    • Glaser NS, Wootton-Gorges SL, Buonocore MH, Tancredi DJ, Marcin JP, Caltagirone R, et al. Subclinical cerebral edema in children with diabetic ketoacidosis randomized to 2 different rehydration protocols. Pediatrics. 2013;131:e73–80. As a follow-up to the 2001 NEJM publication, this study re-evaluated the risk of rapid rehydration and cerebral edema and did not find an increased risk.CrossRefPubMedPubMedCentralGoogle Scholar
  29. 29.
    DeCourcey DD, Steil GM, Wypij D, Agus MS. Increasing use of hypertonic saline over mannitol in the treatment of symptomatic cerebral edema in pediatric diabetic ketoacidosis: an 11-year-old retrospective analysis of mortality. Pediatr Crit Care Med. 2013;14(7):694–700. Scholar
  30. 30.
    Marcin JP, Glaser N, Bernett P, McCaslin I, Nelson D, Trainor J, et al. Factors associated with adverse outcomes in children with diabetic ketoacidosis-related cerebral edema. J Pediatr. 2002;141(6):793–7.CrossRefGoogle Scholar
  31. 31.
    Pasquel FJ, Umpierrez GE. Hyperosmolar hyperglycemic state: a historic review of the clinical presentation, diagnosis, and treatment. Diabetes Care. 2014;37(11):3124–31. Scholar
  32. 32.
    Correll CU. Monitoring and management of antipsychotic-related metabolic and endocrine adverse events in pediatric patients. Int Rev Psychiatry. 2008;20(2):195–201. Scholar
  33. 33.
    Fournier SH, Weinzimer SA, Levitt Katz LE. Hyperglycemic hyperosmolar non-ketotic syndrome in children with type 2 diabetes. Pediatr Diabetes. 2005;6:129–35.CrossRefGoogle Scholar
  34. 34.
    •• Zeitler P, Hagg A, Rosenbloom A, Glaser N: Drigs and Therapeutics Committee of the Lawson Wilkins Pediatric Endocrine Society. Hyperglycemic hyperosmolar syndrome in children: pathophysiological considerations and suggested guidelines for treatment. J Pediatr 2011; 158(1): 9–14.e1–2. Doi: Following the increasing incidence of HHS in pediatrics, these guidelines established critical parameters of care.
  35. 35.
    Rosenbloom AL. Hyperglycemic hyperosmolar state: an emerging pediatric problem. J Pediatr. 2010;156(2):180–4. Scholar
  36. 36.
    Canarie MF, Bogue CW, Banasiak KJ, Weinzimer SA, Tamborlane WV. Decompensated hyperglycemic hyperosmolarity without significant ketoacidosis in the adolescent and young adult population. J Pediatr Endocrinol Metab. 2007;20:1115–24.CrossRefGoogle Scholar
  37. 37.
    Kilbane BJ, Mehta S, Backeljauw PF, Shanley TP, Crimmins NA. Approach to management of malignant hyperthermia-like syndrome in pediatric diabetes mellitus. Pediatr Crit Care Med. 2006;7(2):169–73.CrossRefGoogle Scholar
  38. 38.
    Faustino EV, Apkon M. Persistent hyperglycemia in critically ill children. J Pediatr. 2005;146(1):30–4.CrossRefGoogle Scholar
  39. 39.
    Wintergerst KA, Buckingham B, Gandrud L, Wong BJ, Kache S, Wilson DM. Association of hypoglycemia, hyperglycemia, and glucose variability with morbidity and death in the pediatric intensive care unit. Pediatrics. 2006;118(1):173–9.CrossRefGoogle Scholar
  40. 40.
    Srinivasan V, Spinella PC, Drott HR, Roth CL, Helfaer MA, Nadkarni V. Association of timing, duration, and intensity of hyperglycemia with intensive care unit mortality in critically ill children. Pediatr Crit Care Med. 2004;5(4):329–36.CrossRefGoogle Scholar
  41. 41.
    Yung M, Wilkins B, Norton L, Slater A, Paediatric Study Group, Australian and New Zealand Intensive Care Society. Glucose control, organ failure, and mortality in pediatric intensive care. Pediatr Crit Care Med. 2008;9(2):147–52. Scholar
  42. 42.
    Vlasselaers D, Milants I, Desmet L, Wouters PJ, Vanhorebeek I, van den Heuvel I, et al. Intensive insulin therapy for patients in paediatric intensive care: a prospective, randomised controlled study. Lancet. 2009;373(9663):547–56. Scholar
  43. 43.
    Agus MS, Steil GM, Wypij D, Costello JM, Laussen PC, Langer M, et al. Tight glycemic control versus standard care after pediatric cardiac surgery. N Engl J Med. 2012;367(13):1208–19.CrossRefGoogle Scholar
  44. 44.
    Macrae D, Grieve R, Allen E, Sadique Z, Morris K, Pappachan J, et al. A randomized trial of hyperglycemic control in pediatric intensive care. N Engl J Med. 2014;370(2):107–18. Scholar
  45. 45.
    Agus MS, Wypij D, Hirshberg EL, Srinivasan V, Faustino EV, Luckett PM, et al. HALF-PINT Study Investigators and the PALISI Network. Tight glycemic control in critically ill children. N Engl J Med. 2017;376(8):729–41. Scholar
  46. 46.
    Chen L, Li T, Fang F, Zhang Y, Faramand A. Tight glycemic control in critically ill pediatric patients: a systematic review and meta-analysis. Crit Care. 2018;22(1):57. Scholar
  47. 47.
    Umpaichitra V, Banerji MA, Castells S. Autoantibodies in children with type 2 diabetes mellitus. J Pediatr Endocrinol Metab. 2002;15(Suppl 1):525–30.PubMedGoogle Scholar
  48. 48.
    Dabelea D, Mayer-Davis EJ, Saydah S, Imperatore G, Linder B, Divers J, et al. Prevalence of type 1 and type 2 diabetes among children and adolescents from 2001 to 2009. JAMA. 2014;311(17):1778–86. Scholar
  49. 49.
    Chiang JL, Maahs DM, Garvey KC, Hood KK, Laffel LM, Weinzimer SA, et al. Type 1 diabetes in children and adolescents: a position statement by the American Diabetes Association. Diabetes Care. 2018;41(9):2026–44. Scholar
  50. 50.
    American Diabetes Association. 13. Children and adolescents: Standards of Medical Care in Diabetes – 2019. Diabetes Care. 2019;42(Suppl. 1):S148–64. Scholar
  51. 51.
    Beck J, Greenwood DA, Blanton L, Bollinger ST, Butcher MK, Condon JE, et al. 2017 National Standards for Diabetes Self-Management Education and Support. Diabetes Care. 2017;40(10):1409–19. Scholar
  52. 52.
    •• The Diabetes Control and Complications Trial Research Group. The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus. N Engl J Med. 1993;329:977–86. This historical and landmark study established, for the first time, the link between decreased microvascular complications and tight glycemic control.CrossRefGoogle Scholar
  53. 53.
    Rosenbauer J, Dost A, Karges B, Hungele A, Stahl A, Bachle C, et al. Improved metabolic control in children and adolescents with type 1 diabetes: a trend analysis using prospective multicenter data from Germany and Austria. Diabetes Care. 2012;35:80–6. Scholar
  54. 54.
    Danne T, Phillip M, Buckingham BA, Jarosz-Chobot P, Saboo B, Urakami T, et al. Insulin treatment in children and adolescents with diabetes. Pediatr Diabetes. 2018;2018(19):115–35. Scholar
  55. 55.
    • TODAY Study Group, Zeitler P, Hirst K, Pyle L, Linder B, Copeland K, et al. A clinical trial to maintain glycemic control in youth with type 2 diabetes. N Engl J Med. 2012;366(24):2247–56. This report from the TODAY trial identified the high risk of treatment failure with metformin alone in children with type 2 diabetes and led to more aggressive recommendations in care early after diagnosis.CrossRefPubMedCentralGoogle Scholar
  56. 56.
    Phelan H, King B, Anderson D, Crock P, Lopez P, Smart C. Young children with type 1 diabetes can achieve glycemic targets without hypoglycemia: results of a novel intensive diabetes management program. Pediatr Diabetes. 2018;19(4):769–75. Scholar
  57. 57.
    Jefferies C, Rhodes E, Rachmiel M, Agwu JC, Kapellen T, Abdulla MA, et al. ISPAD Clinical Practice Consensus Guidelines 2018: Management of children and adolescents with diabetes requiring surgery. Pediatr Diabetes. 2018;19(Suppl 27):227–36. Scholar
  58. 58.
    Bristol Meyers Squibb. Retrieved from
  59. 59.
    American Diabetes Association. 15. Diabetes care in the hospital: Standards of Medical Care in Diabetes – 2019. Diabetes Care. 2019;42(Suppl. 1):S173–81. Scholar
  60. 60.
    Umpierrez GE, Klonoff DC. Diabetes technology update: use of insulin pumps and continuous glucose monitoring in the hospital. Diabetes Care. 2018;41:1579–89. Scholar
  61. 61.
  62. 62.
    Retrieved from Insulet Corporation 2018.
  63. 63.
    Retrieved from Tandem Diabetes Care 2019.
  64. 64.
    Fattorusso V, Nugnes R, Casertano A, Valerio G, Mozzillo E, Franzese A. Non-diabetic hyperglycemia in the pediatric age: why, how, and when to treat? Curr Diab Rep. 2018;18(12):140. Scholar
  65. 65.
    Burt MG, Roberts GW, Aguilar-Loza NR, Frith PS, Stranks SN. Continuous monitoring of circadian glycemic patterns in patients receiving prednisolone for COPD. J Clin Endocrinol Metab. 2011;96:1789–96. Scholar
  66. 66.
    Yuen KC, McDaniel PA, Riddle MC. Twenty-four-hour profiles of plasma glucose, insulin, C-peptide and free fatty acid in subjects with varying degrees of glucose tolerance following short-term, medium-dose prednisone (20 mg/day) treatment: evidence for differing effects on insulin secretion and action. Clin Endocrinol. 2012;77:224–32. Scholar
  67. 67.
    Radhakutty A, Burt MG. Management of endocrine disease: critical review of the evidence underlying management of glucocorticoid-induced hyperglycaemia. Eur J Endocrinol. 2018;179(4):R207–18. Scholar
  68. 68.
    Nettles AT. Patient education in the hospital. Diabetes Spectrum. 2005;18(1):44–8. Scholar

Copyright information

© Springer Science+Business Media, LLC, part of Springer Nature 2019

Authors and Affiliations

  1. 1.Division of Pediatric EndocrinologyRichmond University Medical CenterStaten IslandUSA
  2. 2.Weill Cornell Medicine, Division of Pediatric EndocrinologyNY Presbyterian HospitalNew YorkUSA

Personalised recommendations